Media

PSYCHED WELLNESS LTD Annouces Launch of New Bottle Size 60ml

Posted: Feb 01, 2023

Psyched Wellness Announces Launch of eCommerce Fulfillment with ShipHero

Posted: Jan 24, 2023

Psyched Wellness Announces Purchase Agreement with Choice Wholesale for 60,000 Units of Their Amanita Muscaria Tincture, 'Calm'

Posted: Nov 08, 2022

Psyched Wellness Delivers Pre-Orders of Calm and Reopens Online Store

Posted: Nov 02, 2022

Psyched Wellness Announces Successful Pilot Run, Final Flavour Profile for Calm and Shipping Pre-Orders in October

Posted: Sept 27, 2022

Psyched Wellness Provides Corporate Update

Posted: Sept 06, 2022

Psyched Wellness Announces eCommerce Fulfillment Partnership With ShipHero

Posted: Aug 25, 2022

Psyched Wellness Announces Findings From an Ongoing Study With the National Research Council of Canada

Posted: Jul 26, 2022

Psyched Wellness Commences Preorders for Calm in Path to Commercialization of Proprietary Amanita Muscaria Extract

Posted: Jul 19, 2022

Psyched Wellness Announces July 19th, 2022 as the Official Date To Commence Pre-Orders for Calm

Posted: Jul 13, 2022

Psyched Wellness Announces Date for Their Pilot Production Run of the First Legal Amanita Muscaria Tincture Product, Calm

Posted: Jun 29, 2022

Psyched Wellness Announces the Official Launch of Their New eCommerce Online Store

Posted: Jun 14, 2022

Psyched Wellness Receives $226,500 From Sale of Non-Core Assets

Posted: May 25, 2022

Psyched Wellness Announces Del Mahabadi to Join as International Marketing Manager

Posted: May 05, 2022

Psyched Wellness Provides Update on Annual General and Special Meeting

Posted: May 03, 2022

Psyched Wellness Announces Key Findings from the 90-Day Oral Toxicity Study on AME-1

Posted: Apr 26, 2022

Psyched Wellness Announces Share Purchase by Chief Executive Officer, Jeffrey Stevens

Posted: Apr 19, 2022

Psyched Wellness to Participate in Upcoming Investor Conferences in April 2022

Posted: Apr 12, 2022

Psyched Wellness Unveils New Product Name and Visual Identity Elements

Posted: Mar 30, 2022

Psyched Wellness and the National Research Council of Canada Announce Preliminary Data from Studies of Neuroprotective Properties of AME-1

Posted: Mar 24, 2022

Psyched Wellness GRAS Dossier Approved by Panel of Experts, Providing Green Light to Market Products in the United States

Posted: Mar 08, 2022

Psyched Wellness Announces Key Findings from the 90-Day Oral Toxicity Study on AME-1

Posted: Feb 15, 2022

Psyched Wellness Announces Additional Positive Results From The 14-Day Oral Toxicity Study Of AME-1

Posted: Feb 03, 2022

Psyched Wellness Announces Launch of New Logo, Branding, and Website, Prepares to Release Industry-First Amanita Muscaria Tincture

Posted: Feb 01, 2022

Psyched Wellness Provides Update on Anti-Inflammatory Study with the National Research Council of Canada

Posted: Jan 26, 2022

Psyched Wellness Announces Vantage Hemp Co. as Contract Manufacturing Organization Partner to Bring AME-1-derived Products to Market

Posted: Jan 18, 2022

Psyched Wellness Announces Path to Market for AME-1 Derived Products in the USA

Posted: Dec 16, 2021

Psyched Wellness Hires Del Mahabadi as Digital Marketing Consultant to Drive AME-1 Product Launch

Posted: Dec 14, 2021

Psyched Wellness Announces Completion of Its 90 Day Oral Toxicity Study

Posted: Dec 06, 2021

Psyched Wellness Presents AME-1 to Health Canada in Pre-Submission Meeting

Posted: Dec 01, 2021

Psyched Wellness to Present at H.C. Wainwright 2nd Annual Psychedelics Conference, 2021

Posted: Nov 30, 2021

Psyched Wellness Appoints Chief Commercial Officer to Lead Sales and Marketing of AME-1 and Launch CPG Products

Posted: Nov 23, 2021

Psyched Wellness to Present at Grizzle Psychedelics Con on Monday, November 22, 2021

Posted: Nov 17, 2021

Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully Added to the Natural Health Products Ingredients Database (NHPID) of Canada

Posted: Nov 03, 2021

Psyched Wellness Announces Participation in Microdose's Wonderland: Miami on November 8-9, 2021

Posted: Nov 01, 2021

Psyched Wellness Announces Commencement of Next Pre-Clinical Study on AME-1

Posted: Oct 07, 2021

Psyched Wellness Announces Inclusion in AdvisorShares Psychedelics Exchange Traded Fund (ETF)

Posted: Sept 22, 2021

Psyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim for AME-1

Posted: Sept 21, 2021

Psyched Wellness Announces Participation in the H.C. Wainwright 23rd Annual Global Investment Conference

Posted: Sept 10, 2021

Psyched Wellness Commences Neurobehavioral Preclinical Trial Study on AME-1

Posted: Sept 08, 2021

Psyched Wellness Submits Applications for Four Further Provisional Patents Surrounding Its Work on the AME-1

Posted: Aug 17, 2021

Psyched Wellness Enters Into a Service Agreement With CannaLabs to Begin Stability Tests on AME-1

Posted: Jul 26, 2021

Psyched Wellness Announces Filing of Amended and Restated MD&A

Posted: Jul 22, 2021

Psyched Wellness Successfully Completes Its Largest Extraction and Shipment of AME-1 to Asia

Posted: Jul 22, 2021

Amanda Galbraith, Principal at Navigator Joins the Board of Psyched Wellness

Posted: Jul 07, 2021

Psyched Wellness Receives Positive Results From Its 14 Day Oral Toxicity Preclinical Study

Posted: Jul 06, 2021

Psyched Wellness Announces Matthew Singh Joins Team as CPG and Branding Consultant

Posted: Jun 30, 2021

Psyched Wellness Commences Next Pre-Clinical Study on AME-1

Posted: Jun 28, 2021

Psyched Wellness Ltd. to Present at H.C. Wainwright Conference on June 17, 2021

Posted: Jun 10, 2021

Psyched Wellness Hires Ad Agency, dacs Marketing to Build the Branding and Marketing Strategy for AME-1

Posted: Jun 03, 2021

Psyched Wellness to Present at the Psychedelic Investment Series on Monday, May 31, 2021

Posted: May 12, 2021

Psyched Wellness Hires the National Research Council of Canada to Test AME-1

Posted: May 11, 2021

Psyched Wellness Signs Supply Agreement for Amanita Muscaria

Posted: May 04, 2021

Psyched Wellness Initiates the Next Pre-Clinical Trial Study on AME-1

Posted: Apr 27, 2021

Psyched Wellness Receives DTC Eligibility

Posted: Apr 14, 2021

Psyched Wellness Initiates Study on AME-1 Extract for Gut Health

Posted: Mar 30, 2021

Psyched Wellness Submits a Provisional Patent Application for AME-1

Posted: Mar 17, 2021

Psyched Wellness Announces Changes to the Board of Directors

Posted: Mar 15, 2021

Psyched Wellness Closes $6,603,000 Bought Deal Private Placement

Posted: Feb 17, 2021

Psyched Wellness Provides Update on Antioxidant and Anti-Inflammatory Study of Muscimol

Posted: Feb 04, 2021

Psyched Wellness to Participate in Canaccord Genuity's New Paradigms and Treatment Approaches in Mental Health Conference

Posted: Feb 02, 2021

Psyched Wellness Included in First Psychedelic Exchange Traded Fund

Posted: Jan 26, 2021

Re-Release Psyched Wellness Upsizes Previously Announced Bought Deal Offering

Posted: Jan 25, 2021

Psyched Wellness to Present at Inaugural KCSA Psychedelics Investor Conference

Posted: Jan 25, 2021

Psyched Wellness Upsizes Previously Announced Bought Deal Offering

Posted: Jan 22, 2021

Psyched Wellness Announces C$3M Bought Deal Private Placement Led by Canaccord Genuity

Posted: Jan 21, 2021

Psyched Wellness Announces New OTCQB Ticker: PSYCF

Posted: Jan 19, 2021

Psyched Wellness Completes Initial Data Review to Determine Clinical Path for Muscimol

Posted: Jan 14, 2021

Psyched Wellness Commences Antioxidant and Anti-Inflammatory Study on Muscimol

Posted: Jan 06, 2021

Psyched Wellness Has Commenced Research on Muscimol for Various Ailments

Posted: Dec 28, 2020

Psyched Wellness Commences Pre-Clinical Trials of Amanita Muscaria

Posted: Dec 23, 2020

Psyched Wellness Successfully Completes Extraction of a Legal Psychedelic Mushroom

Posted: Dec 15, 2020

Psyched Wellness Successfully Completes Writing the Final Extraction Protocol, the Assembly of Safety & Efficacy Narratives, and Writing the Safety Data Sheet (SDS) For Its First Product

Posted: Dec 10, 2020

Psyched Wellness Advisor Kevin Feeney Releases Book on Amanita Muscaria

Posted: Dec 09, 2020

Psyched Wellness LTD. Adds Aaron Slater to the Advisory Board

Posted: Dec 08, 2020

Psyched Wellness Announces Positive Toxicology Assessment and Provides Path to Market for a Legal Psychedelic Mushroom Product

Posted: Dec 07, 2020

Psyched Wellness Announces Successful Up-Listing to the OTCQB Venture Market

Posted: Dec 02, 2020

Psyched Wellness LTD. Adds Kevin Feeney to the Advisory Board

Posted: Nov 25, 2020

Psyched Wellness LTD. Announces Insider Buying and Option Grant to Professor Nutt

Posted: Nov 18, 2020

Psyched Wellness LTD. Adds Professor David Nutt to the Board of Directors

Posted: Nov 16, 2020

Psyched Wellness LTD. Applied to Up-List to the OTCQB and DTC Eligibility

Posted: Nov 12, 2020

Psyched Wellness LTD. Advisor, Professor David Nutt to Speak at PsyTech Conference

Posted: Oct 27, 2020

Psyched Wellness LTD. Adds Scientific Advisor and Grants Stock Options

Posted: Oct 26, 2020

Psyched Wellness LTD. To Commence Trading on the CSE on October 22, 2020

Posted: Oct 21, 2020

Psyched Wellness Announces Closing of Final Tranche of Non-Brokered Private Placement

Posted: Jul 31, 2020

Duncan Park Announces Name Change to Psyched Wellness LTD.

Posted: Jul 13, 2020

Duncan Park Holdings Corporation Announces Results of Annual and Special Meeting

Posted: Jul 02, 2020

Duncan Park Holdings Corporation Announces Closing of Second Tranche of Non-Brokered Private Placement

Posted: Jun 01, 2020

Duncan Park Holdings Corporation Announces Closing of First Tranche of Non-Brokered Private Placement

Posted: May 25, 2020

Duncan Park Holdings Corporation Announces Non-Brokered Private Placement of Common Shares

Posted: May 11, 2020

Duncan Park Holdings Corporation Announces the Appointment of Christopher Hazelton to the Board of Directors

Posted: Mar 09, 2020

Duncan Park Holdings Corporation Appoints a New Chief Financial Officer

Posted: Jan 27, 2020